Literature DB >> 8077060

Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor.

K Naito1, N Kanbayashi, S Nakajima, T Murai, K Arakawa, S Nishimura, A Okuyama.   

Abstract

The effects of a new metalloproteinase inhibitor, BE16627B [L-N-(N-hydroxy-2-isobutylsuccinynamoyl)-seryl-L-valine, MW: 375.2] isolated from microbial cultures, on human tumor cell growth in nude mice were investigated. BE16627B inhibited metalloproteinases in enzyme assays, as well as gelatinolysis and collagenolysis in cell cultures. BE16627B at 100 micrograms/ml showed no apparent cytotoxicity to human tumor cells in culture and its LD50 in mice was more than 1,000 mg/kg (i.p.). The effects of BE16627B on the in vivo growth of 2 human tumor cell lines were examined: HT1080 fibrosarcoma, which overproduces metalloproteinases, and HCT116 colon carcinoma, which barely secretes metalloproteinases. When BE16627B was administered to mice at 2 mg/mouse/day by an osmotic pump implanted s.c. for 3 weeks from 1 week after i.v. inoculation of HT1080 cells, the number and size of nodules of HT1080 cells on the lung surface were reduced to 24.3 and 46.4%, respectively, of those of controls, and the increase in lung weight due to tumor-cell growth was inhibited 85.5% without body-weight loss. Moreover, BE16627B inhibited 71.2% of the growth of HT1080 cells inoculated s.c. into mice under the same conditions, but did not significantly inhibit the s.c. growth of HCT116 human colon-carcinoma cells. Thus, BE16627B inhibited metalloproteinase-dependent human tumor-cell growth as well as lung colonization without showing cytotoxicity in nude mice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077060     DOI: 10.1002/ijc.2910580518

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.

Authors:  Hideo Maki; Kanji Hojo; Hidekazu Tanaka; Takuko Yamada Sawada; Ryuji Maekawa; Takayuki Yoshioka
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 2.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

3.  Suppression of cell invasion on human malignant glioma cell lines by a novel matrix-metalloproteinase inhibitor SI-27: in vitro study.

Authors:  M Noha; D Yoshida; K Watanabe; A Teramoto
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

4.  Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor.

Authors:  R Maekawa; H Maki; T Wada; H Yoshida; K Nishida-Nishimoto; H Okamoto; Y Matsumoto; H Tsuzuki; T Yoshioka
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Effect of matrix metalloproteinase inhibition on colonic anastomotic healing in rats.

Authors:  T Kiyama; M Onda; A Tokunaga; D T Efron; A Barbul
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

6.  Suppression of matrix metalloproteinase-2 and -9 mediated invasiveness by a novel matrix metalloproteinase inhibitor, BE16627B.

Authors:  K Watanabe; D Yoshida; M Noha; A Teramoto
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

7.  Suppression of matrix metalloproteinase activity by SI-27: detection by a new activity assay with S-2444, a specific chromogenic peptide.

Authors:  Daizo Yoshida; Kunihiro Watanabe; Masahiro Noha; Hiroshi Takahashi; Akira Teramoto
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

8.  Drug-induced apoptosis by a matrix metalloproteinase inhibitor, SI-27 on human malignant glioma cell lines; in vitro study.

Authors:  Ryuzaburo Kanazawa; Daizo Yoshida; Hiroshi Takahashi; Yuichi Sugisaki; Satoru Suzuki; Akira Teramoto
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

9.  Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases.

Authors:  O Santos; C D McDermott; R G Daniels; K Appelt
Journal:  Clin Exp Metastasis       Date:  1997-09       Impact factor: 5.150

10.  Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis.

Authors:  J G Conway; S J Trexler; J A Wakefield; B E Marron; D L Emerson; D M Bickett; D N Deaton; D Garrison; M Elder; A McElroy; N Willmott; A J Dockerty; G M McGeehan
Journal:  Clin Exp Metastasis       Date:  1996-03       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.